Zdrowie i gospodarka · 13/05/2013
FDA Clears Dapiprazole Hydrochloride Ophthalmic Solution for Approval
The FDA has determined that REV-EYES (dapiprazole hydrochloride ophthalmic solution, 0.5%) was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of the medication through abbreviated new drug applications.
Source: Federal Register — Food and Drug AdministrationOpen original release →